AirNexis Therapeutics
PrivateLast Round
Series A
Jan 9, 2026
Est. Valuation
$341.7M
Total Funding Raised
$200M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AirNexis Therapeutics operates in Healthcare & Life Sciences and is based in Palo Alto, California. Its latest recorded funding round was a Series A round in January 2026.
AirNexis Therapeutics is a biotechnology company developing clinical-stage therapies for chronic obstructive pulmonary disease (COPD) and other pulmonary conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AirNexis Therapeutics Comparables
Compare AirNexis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Merck & Co., Inc. | 83% | |
| AeroRx Therapeutics | 82% | |
| Aeriant Therapeutics AB | 78% |
For institutional investors. Book with your work email.
AirNexis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 9, 2026 | ||||
| Series A | Jan 9, 2026 |
For institutional investors. Book with your work email.
AirNexis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series A |
| Enavate Sciences | Series A |
| Life Sciences at Goldman Sachs Alternatives | Series A |
| OrbiMed | Series A |
| Frazier Life Sciences | Series A |
| Goldman Sachs Alternatives | Series A |
| SR One | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
Grew 38% QoQ, from 8 to 11 employees.
- Aug 21, 2026
Monthly visitors increased 52% MoM.
For institutional investors. Book with your work email.
AirNexis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AirNexis Therapeutics's valuation, stock price, and market status.
Is AirNexis Therapeutics a public or private company?
AirNexis Therapeutics is a private company.
What is the current stock price of AirNexis Therapeutics?
AirNexis Therapeutics is a private company, so its shares have no public market price. Caplight tracks AirNexis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AirNexis Therapeutics worth (valuation)?
AirNexis Therapeutics's valuation is estimated at $341.7M based on funding round data.
Can I buy AirNexis Therapeutics stock?
AirNexis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AirNexis Therapeutics's last funding round?
AirNexis Therapeutics's most recent funding round was Series A on January 9, 2026.
Who are the main investors in AirNexis Therapeutics?
Key investors in AirNexis Therapeutics include Frazier Life Sciences.
Will AirNexis Therapeutics IPO soon?
No public IPO plans have been announced for AirNexis Therapeutics.
How can I track AirNexis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in AirNexis Therapeutics's shares on secondary markets.